Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy

doi:10.21037/tcr-21-2886

HFCAS OpenIR

	Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy
	Zhang, Yanqiang 1; Xu, Xiaoqing 2; Hu, Can 2; Du, Yian 1; Ding, Guangyu 1; Chen, Jiahui 1; Zhu, Xiu 3; Xu, Zhiyuan 1,6; Wei, Qing 4,5
	2022-07-01
发表期刊	TRANSLATIONAL CANCER RESEARCH
ISSN	2218-676X
通讯作者	Xu, Zhiyuan(getfar@foxmail.com) ; Wei, Qing(weiqingmd@163.com)
摘要	Background: Conversion surgery is a treatment that aims for R0 resection of primary advanced gastric cancers (GCs) that have responded well to systemic chemotherapy. We investigated the role of conversion therapy in initially unresectable metastatic cancer with positive HER2 status that responded to chemotherapy plus trastuzumab. Methods: A total of 32 metastatic GC patients who underwent systemic chemotherapy plus trastuzumab sequenced by conversion surgery at Zhejiang Cancer Hospital between 2015 and 2020 were retrospectively reviewed. Results: The observed overall survival (OS) and progression-free survival (PFS) for all the patients were 30.2 and 25.1 months, respectively. The 1-year survival rate was 81.25%, and the 1-year PFS rate was 78.13%. Univariate and multivariate analyses demonstrated that liver metastasis (P=0.021), peritoneal metastasis (P=0.047), para-aortic lymph node metastasis (16a1/b2) (P=0.048), macroscopic type 4 (P=0.027), number of noncurative factors (P=0.011), Yoshida et al. category (P=0.021), and inductive chemotherapy cycles (P=0.025) were independent prognostic factors for OS. Conclusions: HER2-positive patients with potentially resectable disease had a remarkably good prognosis after conversion gastrectomy following trastuzumab treatment. Adequate selection of metastatic GC patients for conversion surgery is recommended.
关键词	Gastric cancer HER2-positive conversion therapy
DOI	10.21037/tcr-21-2886
关键词[WOS]	NIVOLUMAB PLUS CHEMOTHERAPY ; GASTROESOPHAGEAL JUNCTION ; OPEN-LABEL ; PHASE-II ; OXALIPLATIN ; SURGERY
收录类别	SCI
语种	英语
资助项目	Medical Health Science and Technology Project of Zhejiang Provincial Health Commission[2022KY684]
项目资助者	Medical Health Science and Technology Project of Zhejiang Provincial Health Commission
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000811139700001
出版者	AME PUBLISHING COMPANY
引用统计	被引频次：3[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/130386
专题	中国科学院合肥物质科学研究院
通讯作者	Xu, Zhiyuan; Wei, Qing
作者单位	1.Chinese Acad Sci, Univ Chinese Acad Sci Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Canc Hosp, Hangzhou, Peoples R China 2.Second Clin Med Coll Zhejiang Chinese Med Univ, Hangzhou, Peoples R China 3.Chinese Acad Sci, Univ Chinese Acad Sci Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Canc Hosp, Hangzhou, Peoples R China 4.Chinese Acad Sci, Univ Chinese Acad Sci Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Canc Hosp, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Basic Med & Canc IBMC, Canc Hosp, 1 East Banshan Rd, Hangzhou 310000, Peoples R China 6.Univ Chinese Acad Sci, Chinese Acad Sci, Inst Basic Med & Canc IBMC, Canc Hosp, 1 East Banshan Rd, Hangzhou 310000, Peoples R China
推荐引用方式 GB/T 7714	Zhang, Yanqiang,Xu, Xiaoqing,Hu, Can,et al. Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy[J]. TRANSLATIONAL CANCER RESEARCH,2022,11.
APA	Zhang, Yanqiang.,Xu, Xiaoqing.,Hu, Can.,Du, Yian.,Ding, Guangyu.,...&Wei, Qing.(2022).Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy.TRANSLATIONAL CANCER RESEARCH,11.
MLA	Zhang, Yanqiang,et al."Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy".TRANSLATIONAL CANCER RESEARCH 11(2022).